Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-391 PK Interaction Study of Atorvastatin and Ezetimibe
NCT02288338Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-391 in hypercholesterolemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve over the dosing interval at steady state for Atorvastatin and Free Ezetimibe at Day 6 and Maximum Plasma Concentration at steady state for Atorvastatin and Free Ezetimibe at Day 6. Started Nov 2014; status: completed.
02
Drugs
CKD-391
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02288338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02288338.